Tirzepatide’s weight-loss evidence is substantial, but a useful overview does more than repeat its largest trial result. Different studies ask whether treatment works, how it compares with another medicine, and what happens when it is withdrawn. The brand and country then determine which uses are actually authorised.
This guide separates those questions. It covers the adult weight-management evidence, the limits of the semaglutide comparison, the sleep-apnoea indication and the safety information that belongs beside any discussion of benefit.
One molecule does not mean one universal indication
Tirzepatide activates GIP and GLP-1 receptors. That mechanism is part of the explanation; the product label supplies the prescribing boundaries. A diabetes product and a weight-management product should not be treated as automatically interchangeable.
| Jurisdiction / product | Verified uses relevant to this guide | What the statement does not establish |
|---|---|---|
| United States / Zepbound | Adult weight reduction and long-term maintenance under the label; moderate-to-severe obstructive sleep apnoea in adults with obesity | Approval for all causes of sleep disturbance, all ages or every tirzepatide product |
| European Union / Mounjaro | Adult weight management with the specified BMI and comorbidity criteria; separate type-2-diabetes indications | Identical wording or indications to US Zepbound, or approval of every proposed use |
Sources: the current US Zepbound prescribing information and EMA’s Mounjaro product record. Both weight-management uses are accompanied by diet and physical-activity measures. The US label describes weekly subcutaneous administration; this article does not provide an initiation, escalation or switching schedule.
Two trials answer two different weight-loss questions
SURMOUNT-1 tested tirzepatide against placebo. SURMOUNT-5 directly randomised participants between tirzepatide and specified semaglutide regimens. They are complementary studies, rather than competing headlines.
| Study | Participants and comparison | Mean change from baseline | Analysis context |
|---|---|---|---|
| SURMOUNT-1 | 2,539 adults with obesity, or overweight plus a weight-related complication; diabetes excluded; double-blind placebo comparison | Tirzepatide 5 mg: −15.0%; 10 mg: −19.5%; 15 mg: −20.9%; placebo: −3.1% | Treatment-regimen estimand in the intention-to-treat population, including treatment discontinuation |
| SURMOUNT-5 | 751 adults without diabetes; open-label comparison of maximum tolerated tirzepatide 10/15 mg with semaglutide 1.7/2.4 mg | Tirzepatide: −20.2%; semaglutide: −13.7% | Least-squares means; treatment-regimen analysis, with specific handling of switching and weight-loss procedures |
The original abstracts are SURMOUNT-1 and SURMOUNT-5. The sponsor’s accompanying publication summary explains the latter analysis definition. The percentages describe average change relative to starting weight. They are not the percentage of participants who lost weight or a guarantee of anyone’s result.
What SURMOUNT-1 establishes
The placebo-controlled trial demonstrates a weight-management effect in its enrolled population over 72 weeks. It also lets readers inspect different research arms within one study, rather than comparing unrelated studies. Randomisation makes that within-study comparison more informative than a before-and-after testimonial.
Its participants did not have diabetes, and its treatment period included escalation and follow-up. The result therefore should not be assigned unchanged to every person with diabetes, every treatment interruption or every duration. Eligibility criteria and average outcomes are different kinds of information: a person meeting label criteria is not thereby promised a trial-average result.
What SURMOUNT-5 adds—and leaves open
SURMOUNT-5 found greater mean weight reduction with tirzepatide than with the semaglutide regimens studied. That is direct comparative evidence, stronger for that specific question than lining up separate placebo-controlled trials. It still does not compare every semaglutide dose, formulation or indication, and it does not answer every safety or health-outcome question.
The study was open-label, so participants and investigators knew the assigned medicine. That feature should remain visible when interpreting the evidence, particularly for experiences reported by participants. Results from one active-comparison trial cannot establish a universal ranking for tolerability, affordability or an individual’s priorities. Our focused semaglutide–tirzepatide comparison goes further into those boundaries.
Stopping treatment is a separate research question
SURMOUNT-4 used a withdrawal design. Participants first received tirzepatide during a 36-week open-label phase. Of 783 people who entered that phase, 670 were then randomised to continue tirzepatide or switch to placebo for another 52 weeks. The two groups were not starting treatment from scratch.
From week 36 to week 88, mean weight change was −5.5% with continued tirzepatide and +14.0% after switching to placebo. Those percentages use the week-36 weight as their reference. They are not simply added to or subtracted from an earlier percentage based on the initial starting weight. The original SURMOUNT-4 abstract supplies the design and results.
The trial supports the importance of a maintenance plan, while its selected continuation population limits generalisation to all people starting treatment. It does not establish a personalised stopping schedule or a universal amount of regain. The weight-regain explainer puts withdrawal evidence in context.
The sleep-apnoea indication has a defined scope
FDA approved Zepbound for moderate-to-severe obstructive sleep apnoea in adults with obesity. Its decision was based on two controlled 52-week studies: one included people using positive airway pressure, and one included people unable or unwilling to use it. The endpoint concerns breathing interruptions during sleep, rather than weight alone. FDA’s approval announcement explains the population and evidence.
An indication for this specific condition does not mean tirzepatide treats all snoring or insomnia. Nor does it instruct someone using positive airway pressure to stop it. Changes to airway treatment require the team managing that condition; improvements on the scale do not substitute for a sleep-related assessment.
Safety information belongs beside efficacy
The US label carries a boxed warning based on thyroid C-cell tumours observed in rats; whether tirzepatide causes those tumours in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2. The distinction between an animal finding, uncertainty in humans and a labelled contraindication matters.
| Issue | Why it matters |
|---|---|
| Gastrointestinal reactions | Nausea, diarrhoea, vomiting and constipation can affect comfort and continuation; severe reactions are also addressed in the label. |
| Dehydration and kidney injury | Fluid loss associated with symptoms requires attention; weight-loss benefit does not remove this risk. |
| Gallbladder disease and pancreatitis | These are separate warnings, rather than ordinary appetite effects. |
| Other medicines | Insulin or certain diabetes medicines can increase hypoglycaemia risk; delayed stomach emptying can affect oral medication absorption. |
| Pregnancy and contraception | The label includes pregnancy precautions and advice relating to oral hormonal contraception. |
| Planned anaesthesia or deep sedation | Delayed gastric emptying and reported aspiration concerns make advance discussion with the procedural team relevant. |
This is a selected overview of the prescribing information, not its complete warnings or a symptom-triage guide. The label’s pooled safety table combines two weight-reduction studies, including one with diabetes. Its frequencies should not be relabelled as the SURMOUNT-1 population or used as a direct comparison with another drug’s unrelated trial. The tolerability guide explains why symptom frequency and discontinuation answer different questions.
Questions a useful treatment discussion should answer
A constructive discussion starts with the intended outcome and the correct approved product. It then considers tolerability, other medicines, reproductive plans, access and follow-up. A higher trial-average reduction does not by itself answer those questions or establish that the highest studied dose is suitable for a particular person.
- Which authorised use and product are being considered?
- How will benefit, adverse effects and continued suitability be assessed?
- What is the plan if treatment becomes difficult to obtain or continue?
- Which existing medicines or planned procedures require discussion?
The current US label does not recommend coadministration with other tirzepatide-containing products or a GLP-1 receptor agonist. This article does not supply combination, conversion or escalation instructions. The before-starting guide offers an information checklist, and the Tirzepatide tracker profile keeps the medicine connected to the wider Drug Tracker.



